Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
5.54
-0.62 (-10.06%)
At close: Oct 16, 2025, 3:59 PM
5.59
0.90%
After-hours: Oct 16, 2025, 07:54 PM EDT
-10.06% (1D)
| Bid | 5.51 |
| Market Cap | 201.11M |
| Revenue (ttm) | 726.33K |
| Net Income (ttm) | -62.13M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -2.92 |
| Forward PE | -3.14 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 5.83 |
| Volume | 1,624,467 |
| Avg. Volume (20D) | 1,865,979.4 |
| Open | 6.10 |
| Previous Close | 6.16 |
| Day's Range | 5.52 - 6.27 |
| 52-Week Range | 1.10 - 10.08 |
| Beta | 0.47 |
| Ex-Dividend Date | n/a |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-13.33%
Immuneering shares are trading lower after the com...
Unlock content with
Pro Subscription
3 weeks ago
+7.45%
Immuneering shares are trading higher after the company reported 86% overall survival at 9 months in first-line pancreatic cancer patients treated with Atebimetinib plus mGnP.
